Clinical Trials Logo
  1. Home
  2. Bronchopulmonary Dysplasia
  3. NCT03808402
  4. Details
NCT03808402 Clinical Trial

The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS

Bronchopulmonary Dysplasia Clinical Trial

— OPTI-SURF  

Official title:
The Effect of Surfactant Dose on Outcomes in Preterm Infants With Respiratory Distress Syndrome

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT03808402
Other study ID # IRAS 237111
Secondary ID 36652
Status Active, not recruiting
Phase
First received
Last updated
Start date October 26, 2018
Est. completion date March 30, 2025

Study information
Verified date August 2023
Source Chiesi UK
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective observational study using de-identified data from the Neonatal Network Research Database (NNRD) supplemented by additional information on dose, method of surfactant administration and dosing frequency to assess whether the dose and method of administration of surfactant given to preterm infants with respiratory distress syndrome (RDS) affects neonatal outcomes.

Description:

The rationale for this study is the clinical relevance of understanding whether surfactant dose affects neonatal outcomes in infants with RDS who are treated in the immediate postnatal period. In a research environment, the dose of surfactant is rigorously controlled, usually administered at a dose of 100mg/kg or 200mg/kg. In clinical practice, clinicians more frequently follow the 'whole vial dosing' approach, where a full vial is given aiming to get as close as possible to the desired dose. Reasons for whole vial use include reduction of waste and administration of surfactant shortly after birth where an infant's weight is unknown. It is unclear whether whole vial dosing leads to under-dosing or over-dosing and whether either situation affects outcomes. Information regarding the dose of surfactant delivered, and the method of administration, are not currently routinely recorded in the UK. The primary objective of the study is to compare two dosing groups (100-130 mg/kg and 170-200 mg/kg) in terms of the proportions of infants who require mechanical ventilation within four days of birth.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 2973
Est. completion date March 30, 2025
Est. primary completion date March 30, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - <37 weeks gestational age Requiring surfactant for Respiratory Distress Syndrome Record of birth weight available Born after study initiation Exclusion Criteria: - 37 weeks gestation age or above Parental opt-out

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United Kingdom William Harvey Hospital Ashford Kent
United Kingdom Birmigham Heartlands Hospital Birmingham
United Kingdom Birmingham Women's Hospital Birmingham
United Kingdom Royal Bolton Hospital Bolton
United Kingdom Bradford Royal Infirmary Bradford
United Kingdom Burnley General Hospital Burnley
United Kingdom The Rosie Hospital Cambridge
United Kingdom St Peter's Hospital Chertsey
United Kingdom University Hospital Coventry Coventry
United Kingdom Hull Royal Infirmary Hull
United Kingdom Leeds General Infirmary Leeds
United Kingdom Leicester Royal Infirmary Leicester
United Kingdom Liverpool Women's Hospital Liverpool
United Kingdom Chelsea and Westminster Hospital London
United Kingdom Guy's and St Thomas' Hospital London
United Kingdom Homerton Hospital London
United Kingdom University College Hospital London
United Kingdom St Mary's Hospital Manchester
United Kingdom Wythenshawe Hospital Manchester
United Kingdom The James Cook Hospital Middlesbrough
United Kingdom University Hospital of North Tees Middlesbrough
United Kingdom Royal Victoria Infirmary Newcastle
United Kingdom Norfolk and Norwich University Hospital Norwich
United Kingdom Queens Medical Centre Nottingham
United Kingdom Royal Oldham Hospital Oldham
United Kingdom John Radcliffe Hospital Oxford
United Kingdom Queen Alexandra Hospital Portsmouth
United Kingdom Jessop Wing Sheffield
United Kingdom Princess Anne Hospital Southampton

Sponsors (3)
Lead Sponsor Collaborator
Chiesi UK Imperial College London, The Leeds Teaching Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Other Effect of dose on need for mechanical ventilation on days 3 and 4 (excluding days 1 and 2) Day 3 to 4 of life
Other Effect of method of administration on need for mechanical ventilation on days 3 and 4 (excluding days 1 and 2) Day 3 to 4 of life
Primary Need for mechanical ventilation Survival without mechanical ventilation (excluding days 1 and 2 of life) Day 3 to 4 of life
Secondary Survival To study completion, an average of 2 years
Secondary Number of doses of surfactant To study completion, an average of 2 years
Secondary Total cumulative dose of surfactant (excluding the first dose) To study completion, an average of 2 years
Secondary Survival with no respiratory support On postnatal day 28
Secondary Survival with no respiratory support 36 weeks gestation
Secondary Survival with no oxygen requirement To study completion, an average of 2 years
Secondary Duration of mechanical ventilation (days) To study completion, an average of 2 years
Secondary Duration of respiratory support (days) To study completion, an average of 2 years
Secondary Two-year developmental outcomes As measured by Bailey's Score Two years
Secondary Two-year developmental outcomes As measured by Composite Developmental Assessment Two years
See also
  Status Clinical Trial Phase
Terminated NCT04506619 - Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Completed NCT04936477 - Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants N/A
Recruiting NCT05285345 - Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Terminated NCT02524249 - Early Versus Late Caffeine for ELBW Newborns N/A
Completed NCT02249143 - Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants N/A
Active, not recruiting NCT01632475 - Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Completed NCT00419588 - Growth of Airways and Lung Tissues in Premature and Healthy Infants
Completed NCT00208039 - Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates N/A
Completed NCT00319956 - Trial II of Lung Protection With Azithromycin in the Preterm Infant Phase 2
Completed NCT00006401 - Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants Phase 3
Terminated NCT05030012 - Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants N/A
Completed NCT00006058 - Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns N/A
Completed NCT00005376 - Premature Birth and Its Sequelae in Women N/A
Completed NCT00011362 - Dexamethasone Therapy in VLBW Infants at Risk of CLD Phase 3
Completed NCT00004805 - Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death N/A
Completed NCT05152316 - The Baby Lung Study
Recruiting NCT04821453 - NAVA vs. CMV Crossover in Severe BPD N/A

External Links